Trials / Completed
CompletedNCT03646864
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Moderate Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-541468 | ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening. |
| OTHER | Placebo | Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening. |
Timeline
- Start date
- 2018-11-15
- Primary completion
- 2019-09-19
- Completion
- 2019-09-19
- First posted
- 2018-08-24
- Last updated
- 2019-09-23
Locations
5 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03646864. Inclusion in this directory is not an endorsement.